JP2018535670A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535670A5
JP2018535670A5 JP2018521983A JP2018521983A JP2018535670A5 JP 2018535670 A5 JP2018535670 A5 JP 2018535670A5 JP 2018521983 A JP2018521983 A JP 2018521983A JP 2018521983 A JP2018521983 A JP 2018521983A JP 2018535670 A5 JP2018535670 A5 JP 2018535670A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
hvr
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535670A (ja
JP6949016B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/075884 external-priority patent/WO2017072210A1/en
Publication of JP2018535670A publication Critical patent/JP2018535670A/ja
Publication of JP2018535670A5 publication Critical patent/JP2018535670A5/ja
Priority to JP2021152748A priority Critical patent/JP7305719B2/ja
Application granted granted Critical
Publication of JP6949016B2 publication Critical patent/JP6949016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521983A 2015-10-29 2016-10-27 抗バリアントFc領域抗体および使用法 Active JP6949016B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021152748A JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192195.4 2015-10-29
EP15192195 2015-10-29
PCT/EP2016/075884 WO2017072210A1 (en) 2015-10-29 2016-10-27 Anti-variant fc-region antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021152748A Division JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Publications (3)

Publication Number Publication Date
JP2018535670A JP2018535670A (ja) 2018-12-06
JP2018535670A5 true JP2018535670A5 (enExample) 2019-11-28
JP6949016B2 JP6949016B2 (ja) 2021-10-13

Family

ID=54361020

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521983A Active JP6949016B2 (ja) 2015-10-29 2016-10-27 抗バリアントFc領域抗体および使用法
JP2021152748A Active JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021152748A Active JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Country Status (10)

Country Link
US (2) US10899845B2 (enExample)
EP (2) EP3368568B1 (enExample)
JP (2) JP6949016B2 (enExample)
KR (2) KR102731208B1 (enExample)
CN (3) CN114891102A (enExample)
AU (1) AU2016344665C1 (enExample)
CA (1) CA3000048A1 (enExample)
IL (2) IL295756A (enExample)
MX (2) MX2018005036A (enExample)
WO (1) WO2017072210A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9731113B2 (en) 2014-12-30 2017-08-15 The Spectranetics Corporation Collapsing coil coupling for lead extension and extraction
US9884184B2 (en) 2014-12-30 2018-02-06 The Spectranetics Corporation Wire hook coupling for lead extension and extraction
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
DK3606955T3 (da) 2017-04-05 2025-01-13 Hoffmann La Roche Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3
WO2019112027A1 (en) * 2017-12-07 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
EP3729080B1 (en) * 2017-12-21 2023-04-19 F. Hoffmann-La Roche AG Universal reporter cell assay for specificity test of novel antigen binding moieties
MY202673A (en) * 2018-07-10 2024-05-14 Regeneron Pharma Modifying binding molecules to minimize pre-existing interactions
WO2020127619A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibodies binding to cd3
EP3956365A4 (en) * 2019-04-19 2023-07-05 Chugai Seiyaku Kabushiki Kaisha ANTIBODIES AND COMPOSITIONS FOR USE IN DETECTING OR CAPTURING A POLYPEPTIDE IN A SAMPLE, AND METHODS FOR DETECTING OR CAPTURING A POLYPEPTIDE IN A SAMPLE
IL296089A (en) 2020-06-19 2022-11-01 Hoffmann La Roche Antibodies binding to cd3
TW202519548A (zh) 2020-06-19 2025-05-16 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
PE20230470A1 (es) * 2020-06-19 2023-03-14 Hoffmann La Roche Moleculas de union al dominio fc de activacion inmunitaria
BR112022024469A2 (pt) 2020-06-19 2023-01-17 Hoffmann La Roche Molécula biespecífica de ativação de células t ativáveis por protease, polipeptídeo específico de idiotipo, composição farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma molécula biespecífica de ativação de células t ativáveis por protease, molécula biespecífica de ativação de células t ativáveis por protease, uso da molécula biespecífica de ativação de células t ativáveis por protease e método para tratar uma doença em um indivíduo
PE20230616A1 (es) 2020-06-19 2023-04-14 Hoffmann La Roche Anticuerpos que se unen a cd3 y folr1
CA3204702A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
CN117858905A (zh) 2021-08-19 2024-04-09 豪夫迈·罗氏有限公司 多价抗变体fc区抗体及使用方法
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
CN118924893A (zh) * 2023-05-10 2024-11-12 信达细胞制药(苏州)有限公司 Bcmap329g抗体及car-t细胞在治疗多发性骨髓瘤中的应用
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU3696289A (en) * 1988-06-08 1990-01-05 Cambridge Bioscience Corporation Anti-fc assay for detection of antibodies
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
ATE180057T1 (de) 1988-11-03 1999-05-15 Igen Int Inc Elektrochemilumineszente testverfahren
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ,インコーポレイテッド 癌マーカー用生物合成結合蛋白質
JPH07509128A (ja) 1992-07-13 1995-10-12 バイオネブラスカ・インコーポレーテッド 組換型ポリペプチドの修飾方法
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1438583B1 (en) 2001-09-20 2009-09-16 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のFcγ受容体IIIaに対する結合活性を高める方法
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk COMPOSITION OF CONDENSED PROTEINS
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
EP2322569B1 (en) 2003-10-09 2020-08-26 Ambrx, Inc. Polymer derivatives for the selective modification of proteins
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたFcレセプター結合親和性及びエフェクター機能をもつCD20抗体
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-tgf-베타 항체
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
SG2014014823A (en) 2009-10-19 2014-07-30 Hoffmann La Roche Non-cross-reactive anti igg antibodies
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
BR112015000665A2 (pt) * 2012-07-13 2017-06-27 Hoffmann La Roche método para a determinação da quantidade de um anticorpo
UA120029C2 (uk) * 2012-07-13 2019-09-25 Рош Глікарт Аг Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
KR102266819B1 (ko) * 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
KR20160104009A (ko) * 2014-01-15 2016-09-02 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 성질을 갖는 Fc-영역 변이체

Similar Documents

Publication Publication Date Title
JP2018535670A5 (enExample)
US11634477B2 (en) Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
CN110431231B (zh) 抗-cd3抗体和包含所述抗体的分子
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2010502183A5 (enExample)
HRP20221141T1 (hr) Anti-lag3 protutijela
TW201915026A (zh) Tigit抗體、其抗原結合片段及醫藥用途
JP2019116474A5 (enExample)
CN110066336B (zh) 抗cd47单克隆抗体、片段及其医药用途
JP2017149720A5 (enExample)
AU2016238246A1 (en) Multi-valent hepatitis B virus antigen binding molecules and uses thereof
RU2012112829A (ru) Анти-gitr-антитела
JP2015506912A5 (enExample)
FI3310812T3 (fi) Anti-her2-vasta-aineita ja käyttömenetelmiä
JP2016516400A5 (enExample)
JP2015508056A5 (enExample)
JP2020524510A5 (enExample)
JP2013535191A5 (enExample)
RU2016118573A (ru) Анти-ly6e антитела и способы применения
JP2013539962A5 (enExample)
RU2012137380A (ru) Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи
RU2013105487A (ru) Антитела против нейропилина и способы их применения
JPWO2021048725A5 (enExample)
HRP20171641T1 (hr) Genetički polimorfizam kod makularne degeneracije vezane uz dob